建立适用于癌症药理学研究的儿童高级别胶质瘤与室管膜瘤活体生物样本库
研究建立了一套标准化方法流程,通过直接三维体外培养儿童最致命的胶质脑肿瘤,快速高效生成患者来源肿瘤类器官(PDT-O)并对其进行生物样本库保存。组织学、分子和药物反应分析显示PDT-O可重现亲本肿瘤特征包括瘤内异质性,且即使在多次传代和冷冻保存/复苏后仍保持该特性。研究在PDT-O上成功进行了标准治疗和新治疗方案的临床前测试,并鉴定ONC201为不限于H3K27变异胶质瘤的儿童胶质肿瘤选择性药物,以及可增强ONC201治疗反应的联合策略。
要点
- 标准化流程可快速高效生成并生物样本库保存儿童胶质脑肿瘤PDT-O。
- PDT-O重现亲本肿瘤组织学、分子特征及瘤内异质性,多次传代和冻存复苏后仍保持。
- PDT-O可用于标准治疗和新方案临床前测试,ONC201对不限于H3K27变异胶质瘤的儿童胶质肿瘤具选择性。
核心结论
- 研究描述了一种快速稳健的流程,用于儿童胶质脑肿瘤PDT-O的生物样本库保存。
- 这些PDT-O模型具有患者特异性建模潜力,即使在体外长期扩增后亦然,并建立了其支持强大临床前研究的概念验证。
研究设计与样本
- 基于本团队专业知识和关于胶质母细胞瘤三维原代培养的文献仔细综述,采用整合方法建立标准化方法流程,用于通过直接三维体外培养儿童最致命胶质脑肿瘤来建立、表征和生物样本库保存PDT-O。
- 为评估PDT-O保真度和验证其临床前相关性,进行了全面的组织学、分子和药物反应分析。
主要发现
- 方法流程允许快速高效生成PDT-O,重现其亲本肿瘤特征包括瘤内异质性,即使在多次传代和作为三维培养物冷冻保存/复苏后亦然。
- 成功在这些PDT-O上对标准治疗和新治疗选择进行了临床前测试反应。
- 鉴定ONC201为儿童胶质肿瘤类型的选择性药物,不限于H3K27变异胶质肿瘤,并鉴定可增加对ONC201治疗反应的联合策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic strategies. In the past decades, patient-derived tumor organoids (PDT-O) have emerged as powerful tools for modeling tumoral cell diversity and dynamics, and they could then help define new therapeutic options for pediatric brain tumors. METHODS: Through an integrative approach based on our expertise and a careful review of the literature about glioblastoma 3D primary cultures, we set up a standardized methodological pipeline for the establishment, characterization, and biobanking of PDT-O through direct 3D in vitro culture of the deadliest pediatric glial brain tumors. To assess PDT-O fidelity and validate their preclinical relevance, we performed comprehensive histological, molecular, and drug-response analyses. RESULTS: Our methodological pipeline allowed the rapid and efficient generation of PDT-O recapitulating their parental tumor features, including intratumoral heterogeneity, even after several passages and cryopreservation/revival as 3D cultures. Moreover, we successfully performed preclinical test responses on these PDT-O to standard-of-care therapies and new therapeutic options. Finally, we identified ONC201 as a selective drug for pediatric glial tumor types not restricted to H3K27-altered glial tumors, as well as combination strategies to increase the therapeutic response to ONC201. CONCLUSIONS: Hence, we describe a fast and robust process to biobank PDT-O for pediatric glial brain tumors. These PDT-O models have the potential for patient-specific modeling even after long-term expansion in vitro, and we established the proof-of-concept of their usefulness to support powerful preclinical studies.
引用
- Deligne C, Tourbez A, Bénard F, et al. Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology. Neuro Oncol. 2025. PMID: 39792378. doi:10.1093/neuonc/noaf007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。